Decoding the Balance Between Diagnostic and Therapeutic Applications in the China Radiopharmaceuticals Market
A deep dive into the China Radiopharmaceuticals Market segment shows that diagnostic agents currently hold the majority of the market share, accounting for over 80% of total revenue. This is primarily due to the widespread use of Technetium-99m for bone scans and Fluorine-18 for oncology PET imaging. However, the therapeutic segment is the fastest-growing area, driven by the recent introduction...
0 Commentaires 0 Parts 110 Vue 0 Aperçu